MX2021010398A - Metodo para tratar un mieloma multiple. - Google Patents

Metodo para tratar un mieloma multiple.

Info

Publication number
MX2021010398A
MX2021010398A MX2021010398A MX2021010398A MX2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A MX 2021010398 A MX2021010398 A MX 2021010398A
Authority
MX
Mexico
Prior art keywords
treating
multiple myeloma
subject
administering
effective amount
Prior art date
Application number
MX2021010398A
Other languages
English (en)
Spanish (es)
Inventor
Marla L Weetall
Liangxian Cao
Arnold Bolomsky
Heinz Ludwig
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021010398A publication Critical patent/MX2021010398A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021010398A 2019-02-28 2020-02-26 Metodo para tratar un mieloma multiple. MX2021010398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962812002P 2019-02-28 2019-02-28
PCT/US2020/019884 WO2020176610A1 (en) 2019-02-28 2020-02-26 Method for treating a multiple myeloma

Publications (1)

Publication Number Publication Date
MX2021010398A true MX2021010398A (es) 2022-01-18

Family

ID=72238680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010398A MX2021010398A (es) 2019-02-28 2020-02-26 Metodo para tratar un mieloma multiple.

Country Status (11)

Country Link
US (1) US20220143016A1 (https=)
EP (1) EP3931196A4 (https=)
JP (1) JP2022521801A (https=)
CN (1) CN113710670A (https=)
AU (1) AU2020227748A1 (https=)
BR (1) BR112021016747A2 (https=)
CA (1) CA3131249A1 (https=)
EA (1) EA202192117A1 (https=)
IL (1) IL285800A (https=)
MX (1) MX2021010398A (https=)
WO (1) WO2020176610A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (https=) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
EP2624818B1 (en) * 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Bortezomib formulations stabilised with boric acid
NZ746607A (en) * 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
EA034866B1 (ru) * 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
EP3836932A2 (en) * 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Also Published As

Publication number Publication date
AU2020227748A1 (en) 2021-09-16
CN113710670A (zh) 2021-11-26
BR112021016747A2 (pt) 2021-10-19
WO2020176610A8 (en) 2021-08-12
IL285800A (en) 2021-10-31
EP3931196A4 (en) 2022-12-14
JP2022521801A (ja) 2022-04-12
CA3131249A1 (en) 2020-09-03
EA202192117A1 (ru) 2021-11-23
WO2020176610A1 (en) 2020-09-03
EP3931196A1 (en) 2022-01-05
US20220143016A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2025003398A (es) Nuevo compuesto tetraheterociclico
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
MY208545A (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
GEP20227443B (en) Magl inhibitors
JOP20210050B1 (ar) معدلات تعبير pnpla3
WO2020183245A3 (en) Anti-v(beta17)/anti-cd123 bispecific antibodies
TN2019000210A1 (en) Antitumoral compounds
PH12013502144A1 (en) Multiple myeloma treatment
CL2020003276A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
JOP20200291A1 (ar) معدلات التعبير عن apol1
MX2021010152A (es) Moduladores de la expresion de malat1.
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
MX2017012759A (es) Moléculas pequeñas que contienen boro como agentes antiprotozoarios.
MX2021014309A (es) Composicion para alimentos de animales que contiene los compuestos del componente hexahidro-?-acido y aplicacion de la misma.
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
IL288864A (en) Treatment that includes sglt inhibitors, for example sglt 1/2 inhibitors
ZA202207328B (en) Zeolite composition suitable for tanning leather
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
MX2016002308A (es) Tratamiento del mieloma multiple.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
MX2021010398A (es) Metodo para tratar un mieloma multiple.